Ads
related to: hemophilia b treatment drugs side effects- Clinical Trial Experience
View Extensive Clinical Trial Data
And Learn About Long Term Safety.
- Hear From Real Patients
See How A Trusted HEM B Treatment
Works. Watch Patient Testimonials.
- Request More Information
Meet With A Representative
Or Find Helpful Resources.
- Calculate Patient Dosage
Find Recommended Intervals For
Personalized & Extended Dosing.
- Clinical Trial Experience
Search results
Results From The WOW.Com Content Network
Concizumab, sold under the brand name Alhemo, is a monoclonal antibody used for the treatment of hemophilia A and hemophilia B. [5] [8] It is an anti-tissue factor pathway inhibitor. [5] [8] The most common adverse reactions include injection site reactions and hives (urticaria). [11]
The most common side effects include injection site reactions, headache, and itching (pruritis). [4] Marstacimab was approved for medical use in the United States in October 2024, [4] and in the European Union in November 2024. [3] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [6]
The safety and effectiveness of etranacogene dezaparvovec were evaluated by the US Food and Drug Administration (FDA) in two studies of 57 adult men 18 to 75 years of age with severe or moderately severe hemophilia B. [7] Effectiveness was established based on decreases in the men's annualized bleeding rate (ABR). [7]
Biogen Idec (BIIB) and Swedish Orphan Biovitrum said a potential hemophilia B treatment has met safety goals in an early-stage study. The study involved 14 previously treated patients, and the ...
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via
In the US, fidanacogene elaparvovec is indicated for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy; or have current or historical life-threatening hemorrhage; or have repeated, serious spontaneous bleeding episodes; and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var ...
Ads
related to: hemophilia b treatment drugs side effects